Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs from the neuroscience-focused biotech. The most promising of these is ...

Drug failures are just a fact of life in pharma, and anytime you see a blue-chip stock like ABBV lose $40 billion in market ...

Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...

AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of ...

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about ...

Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating yesterday. David Risinger’s rating is based on several key considerations surrounding ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...